Literature DB >> 6595963

Multiple-dose pharmacokinetics of imipenem-cilastatin.

G L Drusano, H C Standiford, C Bustamante, A Forrest, G Rivera, J Leslie, B Tatem, D Delaportas, R R MacGregor, S C Schimpff.   

Abstract

We characterized the pharmacokinetic profile of imipenem-cilastatin administered intravenously to six normal volunteers in a dose of 1,000 mg of each drug every 6 h for 40 doses. The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively. The central compartment volumes of distribution for imipenem and cilastatin were 0.16 (+/- 0.05) and 0.14 (+/- 0.03) liter/kg, respectively. Elimination half-lives were short: 0.93 (+/- 0.09) h for imipenem and 0.84 (+/- 0.11) h for cilastatin. Plasma clearances were 12.1 (+/- 0.06) liters/h per 1.73 m2 for imipenem and 12.4 (+/- 1.1) liters/h per 1.73 m2 for cilastatin. Renal clearance accounted for 54% of the plasma clearance of imipenem and 69% of the plasma clearance of cilastatin. The concentrations of imipenem in plasma and urine remained above the MICs of the vast majority of pathogens throughout the dosing interval.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6595963      PMCID: PMC180001          DOI: 10.1128/AAC.26.5.715

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

2.  Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

Authors:  S R Norrby; K Alestig; F Ferber; J L Huber; K H Jones; F M Kahan; M A Meisinger; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

3.  Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.

Authors:  S R Norrby; K Alestig; B Björnegård; L A Burman; F Ferber; J L Huber; K H Jones; F M Kahan; J S Kahan; H Kropp; M A Meisinger; J G Sundelof
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

Review 4.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

5.  Disposition of radiolabeled imipenem and cilastatin in normal human volunteers.

Authors:  S R Norrby; J D Rogers; F Ferber; K H Jones; A G Zacchei; L L Weidner; J L Demetriades; D A Gravallese; J Y Hsieh
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

6.  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.

Authors:  W K Livingston; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

7.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

8.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

9.  In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.

Authors:  J E Brown; V E Del Bene; C D Collins
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

  9 in total
  31 in total

1.  Pharmacokinetics of the penem CP-65,207 and its separate stereoisomers in humans.

Authors:  G Foulds; A K Knirsch; J D Lazar; T G Tensfelt; N Gerber
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.

Authors:  Ben M Lomaestro; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits.

Authors:  S H Kim; W B Kim; M G Lee
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Pharmacokinetic changes during pregnancy and their clinical relevance.

Authors:  R Loebstein; A Lalkin; G Koren
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

5.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

6.  Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Analysis of Paradoxical Efficacy of Carbapenems against Carbapenemase-Producing Escherichia coli in a Murine Model of Lethal Peritonitis.

Authors:  Ariane Roujansky; Victoire de Lastours; François Guérin; Françoise Chau; Geoffrey Cheminet; Laurent Massias; Vincent Cattoir; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

8.  Degradation kinetics of imipenem in normal saline and in human serum.

Authors:  D J Swanson; C DeAngelis; I L Smith; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 9.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

10.  Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.

Authors:  G L Drusano; K I Plaisance; A Forrest; C Bustamante; A Devlin; H C Standiford; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.